Inhaled alpha 1 -proteinase inhibitor therapy in patients with cystic fibrosis

Amit Gaggar(University of Alabama at Birmingham), Scott H. Donaldson(University of North Carolina at Chapel Hill), Henry L. Dorkin(Boston Children's Hospital), Rhonda Griffin(Grifols (United States)), James F. Chmiel(Riley Hospital for Children), Patrick A. Flume(Medical University of South Carolina), Junliang Chen(Sun Yat-sen University), David P. Nichols(Cystic Fibrosis Foundation)
Journal of Cystic Fibrosis
August 29, 2015
10.1016/j.jcf.2015.07.009
Cited by 57

Related Papers

Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del<i>CFTR</i>
|New England Journal of Medicine|2015|1.6k
Randomized Trial of Omalizumab (Anti-IgE) for Asthma in Inner-City Children
|New England Journal of Medicine|2011|870
Effect of VX-770 in Persons with Cystic Fibrosis and the G551D- <i>CFTR</i> Mutation
|New England Journal of Medicine|2010|802
Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the <i>F508del-CFTR</i> mutation
|Thorax|2011|501
Efficacy of Aerosolized Tobramycin in Patients with Cystic Fibrosis
|New England Journal of Medicine|1993|458